Sitagliptin 25 mg Tablets (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Aliko Pharmaceuticals Co., Ltd.
MFDS item code 202101319 · Approved 2021.02.16
This product's status changed to Expired on 2026.02.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication assists in blood glucose control for patients with type 2 diabetes and complements meal and exercise therapy. It can be used alone for patients starting diabetes treatment, and if blood glucose control is difficult with monotherapy, it can be administered in combination with metformin. It can also be added when using sulfonylureas, metformin, thiazolidinedione, or insulin as monotherapy, but blood glucose control remains inadequate. Moreover, it can be used in combination to enhance treatment efficacy if blood glucose control is still difficult with these medications. This medication is useful for improving patients' blood glucose management.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment As dose adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may cause severe hypersensitivity reactions after administration; if allergic symptoms are suspected, discontinue use immediately and consult a healthcare professional. Symptoms of pancreatitis may occur during the use of this medication; therefore, careful observation is required for signs such as abdominal pain or vomiting, and if suspected, discontinue the medication and inform your doctor. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in patients with allergies to this medication or its components. Patients with decreased kidney function may have slower excretion of this medication; therefore, adjustments in dosage are necessary, and regular kidney function testing is important. When used with other diabetes medications that may cause hypoglycemia, there may be an increased risk of hypoglycemia, so symptoms should be carefully monitored and dosage adjusted if necessary. Severe joint pain or the appearance of blisters may occur, and if such symptoms arise, immediate consultation with a doctor is required, and the medication may need to be discontinued if necessary. It is advisable for pregnant or lactating women not to use this medication, and safety in children or adolescents under 18 years of age has not been established. Elderly patients may have a risk of decreased kidney function, so kidney function should be routinely monitored before and after administration. In the case of overdose, general emergency treatment is performed, and if necessary, some of the medication can be removed through dialysis. No significant interactions with other medications have been reported when this medication is used in combination, but it is safe to consult healthcare professionals when used in combination with certain medications.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering. The storage temperature should be maintained between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and safety over time.
Pink, round, biconvex film-coated tablets
PTP - 28 tablets/box [(14 tablets/PTP×2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Aliko Pharmaceuticals Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.